JAMA. 2024 Dec 13. IF: 63.1
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
www.jamanetwork.com/journals/jama/fullarticle/2828232
JAMA. 2024 Dec 13. IF: 63.1
Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
www.jamanetwork.com/journals/jama/fullarticle/2828233
JAMA. 2024 Dec 13. IF: 63.1
Reimagining Luck.
www.jamanetwork.com/journals/jama/fullarticle/2828231
Cancer Cell. 2024 Dec 12. IF: 48.8
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1.
www.cell.com/cancer-cell/fulltext/S1535-6108(24)00443-4
Nat Cancer. 2024 Dec 13. IF: 23.5
How the bone microenvironment shapes the pre-metastatic niche and metastasis.
www.nature.com/articles/s43018-024-00854-6
Cell Mol Immunol. 2024 Dec 13. IF: 21.8
Effective immunosurveillance of clonally expanded mammary aneuploid cells.
www.nature.com/articles/s41423-024-01250-x
Nat Mach Intell. 2024 Dec 13. IF: 18.8
Stable Cox regression for survival analysis under distribution shifts.
www.nature.com/articles/s42256-024-00932-5
Nat Aging. 2024 Dec 13;4:1731-1744. IF: 17.0
Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause.
www.nature.com/articles/s43587-024-00767-0
Nat Aging. 2024 Dec 13;4:1745-1759. IF: 17.0
Genetics of female and male reproductive traits and their relationship with health, longevity and consequences for offspring.
www.nature.com/articles/s43587-024-00733-w
Mil Med Res. 2024 Dec 12;11(1):76. IF: 16.7
Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.
www.biomedcentral.com/articles/10.1186/s40779-024-00582-z
MedComm (2020). 2024 Dec 11;5(12):e70023. IF: 10.7
Multimodal data fusion AI model uncovers tumor microenvironment immunotyping heterogeneity and enhanced risk stratification of breast cancer.
www.onlinelibrary.wiley.com/doi/10.1002/mco2.70023
Clin Cancer Res. 2024 Dec 13. IF: 10.0
Complete remissions of HER2-positive trastuzumab-resistant xenografts using a potent [225Ac]Ac-labeled anti-HER2 antibody-drug radioconjugate.
www.aacrjournals.org/clincancerres/article/750552
